Standardization of assay methods reduces variability of total PSA measurements: an Irish study

Study Type – Diagnosis (quality control) Level of Evidence 2b What's known on the subject? and What does the study add? Today, numerous assays for PSA detection are available from various manufacturers. However, these various assays do not detect PSA equally and several studies have demonstrate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BJU international 2012-09, Vol.110 (5), p.644-650
Hauptverfasser: Forde, James C., Marignol, Laure, Blake, Ophelia, McDermott, Ted, Grainger, Ronald, Crowley, Vivien E., Lynch, Thomas H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 650
container_issue 5
container_start_page 644
container_title BJU international
container_volume 110
creator Forde, James C.
Marignol, Laure
Blake, Ophelia
McDermott, Ted
Grainger, Ronald
Crowley, Vivien E.
Lynch, Thomas H.
description Study Type – Diagnosis (quality control) Level of Evidence 2b What's known on the subject? and What does the study add? Today, numerous assays for PSA detection are available from various manufacturers. However, these various assays do not detect PSA equally and several studies have demonstrated variability between them. In order to harmonise PSA results and reduce the discrepancies, reference materials are available for assay calibration. We have demonstrated significantly variability between 6 different assay methods currently in use in 9 hospitals despite assay calibration. Variability in PSA values was reduced with the standardisation of the assay method in 4 hospitals. Our results highlight the dilemma of PSA assay variability and stress the need for nationwide standardisation of PSA testing. OBJECTIVE •  To determine whether standardization of total prostate‐specific antigen (tPSA) assay methods reduces variability in tPSA measurements. PATIENTS AND METHODS •  Blood samples from 84 patients attending a single urology department were distributed across nine hospitals selected throughout Ireland for the independent determination of tPSA under the same conditions. •  The selected hospitals collectively used six different assay methods for tPSA detection: Beckman Hybritech WHO Calibrated (used as reference method), Tosoh AIA 1800, Roche E170 (used in three hospitals), Abbott AxSYM, Immulite 2500 2nd Generation (used in two hospitals) and Siemens ADVIA Centaur. •  The method of tPSA detection was next standardized in a subset of four hospitals using the same assay method and the measurements were repeated. •  The difference in mean tPSA in the cohort across the hospitals tested was determined and the Bland–Altman test was used to assess the agreement between each test. Analysis was performed over both the full (0.5–30 µg/L, N= 84) and a narrow (3–7 µg/L, n= 25) tPSA range. RESULTS •  The range and the mean tPSA of the full cohort were inflated across the eight test hospitals, when compared with the reference hospital. •  The poorest agreement between assay methods was associated with a bias of 2.2 ± 2.4 µg/L. The variability in tPSA measurements between assay methods was inconsistent across the range of tPSA values tested and increased with increasing mean tPSA. •  Agreement in reported tPSA was excellent after standardization of tPSA assay methods (bias
doi_str_mv 10.1111/j.1464-410X.2011.10923.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1034200175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1034200175</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4283-a485d60b67eb1217934e728c2d917b4685d3e5e53234977ca4df2fd86919fbb3</originalsourceid><addsrcrecordid>eNqNkdtqFTEUhoMott36ChIQwZs9zWkyM14ItVRbKSi0gleGNZMMzWYObVZGOz69me7dFnplbrLI_61D1k8I5Szj6RxuMq60WivOfmaCcZ5xVgmZ3T4j-w_C8_uYVXqPHCBuGEsPOn9J9oQoq0IKvU9-XUQYLATr_0L040DHlgIizLR38Wq0SIOzU-OQ_obgofadj_MCxTFCR79fHCUQcAqud0PEDxQGehY8XlGMk51fkRctdOhe7-4Vufx8cnl8uj7_9uXs-Oh83ShRyjWoMrea1bpwNRe8qKRyhSgbYSte1EonVbrc5VJIVRVFA8q2orWlrnjV1rVckffbstdhvJkcRtN7bFzXweDGCQ1nUon0_SJP6Nsn6GacwpCGM0kWecWYYokqt1QTRsTgWnMdfA9hTqXMYoHZmGW7Ztm0WSwwdxaY25T6ZtdgqntnHxLvd56AdzsAsIGuDTA0Hh85LaUuU60V-bjl_vjOzf89gPn09cddKP8BxGShWg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1752590040</pqid></control><display><type>article</type><title>Standardization of assay methods reduces variability of total PSA measurements: an Irish study</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Forde, James C. ; Marignol, Laure ; Blake, Ophelia ; McDermott, Ted ; Grainger, Ronald ; Crowley, Vivien E. ; Lynch, Thomas H.</creator><creatorcontrib>Forde, James C. ; Marignol, Laure ; Blake, Ophelia ; McDermott, Ted ; Grainger, Ronald ; Crowley, Vivien E. ; Lynch, Thomas H.</creatorcontrib><description>Study Type – Diagnosis (quality control) Level of Evidence 2b What's known on the subject? and What does the study add? Today, numerous assays for PSA detection are available from various manufacturers. However, these various assays do not detect PSA equally and several studies have demonstrated variability between them. In order to harmonise PSA results and reduce the discrepancies, reference materials are available for assay calibration. We have demonstrated significantly variability between 6 different assay methods currently in use in 9 hospitals despite assay calibration. Variability in PSA values was reduced with the standardisation of the assay method in 4 hospitals. Our results highlight the dilemma of PSA assay variability and stress the need for nationwide standardisation of PSA testing. OBJECTIVE •  To determine whether standardization of total prostate‐specific antigen (tPSA) assay methods reduces variability in tPSA measurements. PATIENTS AND METHODS •  Blood samples from 84 patients attending a single urology department were distributed across nine hospitals selected throughout Ireland for the independent determination of tPSA under the same conditions. •  The selected hospitals collectively used six different assay methods for tPSA detection: Beckman Hybritech WHO Calibrated (used as reference method), Tosoh AIA 1800, Roche E170 (used in three hospitals), Abbott AxSYM, Immulite 2500 2nd Generation (used in two hospitals) and Siemens ADVIA Centaur. •  The method of tPSA detection was next standardized in a subset of four hospitals using the same assay method and the measurements were repeated. •  The difference in mean tPSA in the cohort across the hospitals tested was determined and the Bland–Altman test was used to assess the agreement between each test. Analysis was performed over both the full (0.5–30 µg/L, N= 84) and a narrow (3–7 µg/L, n= 25) tPSA range. RESULTS •  The range and the mean tPSA of the full cohort were inflated across the eight test hospitals, when compared with the reference hospital. •  The poorest agreement between assay methods was associated with a bias of 2.2 ± 2.4 µg/L. The variability in tPSA measurements between assay methods was inconsistent across the range of tPSA values tested and increased with increasing mean tPSA. •  Agreement in reported tPSA was excellent after standardization of tPSA assay methods (bias &lt;0.2 µg/L). •  Over the narrow 3–7 µg/L PSA range, 12/25 (48%) patients had a tPSA range of values across all hospitals in excess of 2 µg/L. Following standardization of the tPSA assay method, patient tPSA ranges were &lt;0.5 µg/L for 13/25 (52%) patients. CONCLUSIONS •  We have shown that the lack of standardization of tPSA assay methods across a panel of Irish hospitals leads to significant variability in the measured tPSA values for the same patient samples. •  Variability in tPSA values was reduced with the standardization of the assay method in four hospitals. •  Standardization of PSA testing on a nationwide scale is warranted.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/j.1464-410X.2011.10923.x</identifier><identifier>PMID: 22897326</identifier><identifier>CODEN: BJINFO</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>assay ; Biological and medical sciences ; Cancer Care Facilities ; Cohort Studies ; Early Detection of Cancer - methods ; Early Detection of Cancer - standards ; Gynecology. Andrology. Obstetrics ; Humans ; Immunoassay - standards ; Ireland ; Male ; Male genital diseases ; Medical sciences ; Nephrology. Urinary tract diseases ; prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - diagnosis ; Reference Standards ; Sensitivity and Specificity ; total prostate‐specific antigen ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland ; variability</subject><ispartof>BJU international, 2012-09, Vol.110 (5), p.644-650</ispartof><rights>2012 BJU INTERNATIONAL</rights><rights>2015 INIST-CNRS</rights><rights>2012 BJU INTERNATIONAL.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4283-a485d60b67eb1217934e728c2d917b4685d3e5e53234977ca4df2fd86919fbb3</citedby><cites>FETCH-LOGICAL-c4283-a485d60b67eb1217934e728c2d917b4685d3e5e53234977ca4df2fd86919fbb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1464-410X.2011.10923.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1464-410X.2011.10923.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26336892$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22897326$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Forde, James C.</creatorcontrib><creatorcontrib>Marignol, Laure</creatorcontrib><creatorcontrib>Blake, Ophelia</creatorcontrib><creatorcontrib>McDermott, Ted</creatorcontrib><creatorcontrib>Grainger, Ronald</creatorcontrib><creatorcontrib>Crowley, Vivien E.</creatorcontrib><creatorcontrib>Lynch, Thomas H.</creatorcontrib><title>Standardization of assay methods reduces variability of total PSA measurements: an Irish study</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>Study Type – Diagnosis (quality control) Level of Evidence 2b What's known on the subject? and What does the study add? Today, numerous assays for PSA detection are available from various manufacturers. However, these various assays do not detect PSA equally and several studies have demonstrated variability between them. In order to harmonise PSA results and reduce the discrepancies, reference materials are available for assay calibration. We have demonstrated significantly variability between 6 different assay methods currently in use in 9 hospitals despite assay calibration. Variability in PSA values was reduced with the standardisation of the assay method in 4 hospitals. Our results highlight the dilemma of PSA assay variability and stress the need for nationwide standardisation of PSA testing. OBJECTIVE •  To determine whether standardization of total prostate‐specific antigen (tPSA) assay methods reduces variability in tPSA measurements. PATIENTS AND METHODS •  Blood samples from 84 patients attending a single urology department were distributed across nine hospitals selected throughout Ireland for the independent determination of tPSA under the same conditions. •  The selected hospitals collectively used six different assay methods for tPSA detection: Beckman Hybritech WHO Calibrated (used as reference method), Tosoh AIA 1800, Roche E170 (used in three hospitals), Abbott AxSYM, Immulite 2500 2nd Generation (used in two hospitals) and Siemens ADVIA Centaur. •  The method of tPSA detection was next standardized in a subset of four hospitals using the same assay method and the measurements were repeated. •  The difference in mean tPSA in the cohort across the hospitals tested was determined and the Bland–Altman test was used to assess the agreement between each test. Analysis was performed over both the full (0.5–30 µg/L, N= 84) and a narrow (3–7 µg/L, n= 25) tPSA range. RESULTS •  The range and the mean tPSA of the full cohort were inflated across the eight test hospitals, when compared with the reference hospital. •  The poorest agreement between assay methods was associated with a bias of 2.2 ± 2.4 µg/L. The variability in tPSA measurements between assay methods was inconsistent across the range of tPSA values tested and increased with increasing mean tPSA. •  Agreement in reported tPSA was excellent after standardization of tPSA assay methods (bias &lt;0.2 µg/L). •  Over the narrow 3–7 µg/L PSA range, 12/25 (48%) patients had a tPSA range of values across all hospitals in excess of 2 µg/L. Following standardization of the tPSA assay method, patient tPSA ranges were &lt;0.5 µg/L for 13/25 (52%) patients. CONCLUSIONS •  We have shown that the lack of standardization of tPSA assay methods across a panel of Irish hospitals leads to significant variability in the measured tPSA values for the same patient samples. •  Variability in tPSA values was reduced with the standardization of the assay method in four hospitals. •  Standardization of PSA testing on a nationwide scale is warranted.</description><subject>assay</subject><subject>Biological and medical sciences</subject><subject>Cancer Care Facilities</subject><subject>Cohort Studies</subject><subject>Early Detection of Cancer - methods</subject><subject>Early Detection of Cancer - standards</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunoassay - standards</subject><subject>Ireland</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Reference Standards</subject><subject>Sensitivity and Specificity</subject><subject>total prostate‐specific antigen</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><subject>variability</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkdtqFTEUhoMott36ChIQwZs9zWkyM14ItVRbKSi0gleGNZMMzWYObVZGOz69me7dFnplbrLI_61D1k8I5Szj6RxuMq60WivOfmaCcZ5xVgmZ3T4j-w_C8_uYVXqPHCBuGEsPOn9J9oQoq0IKvU9-XUQYLATr_0L040DHlgIizLR38Wq0SIOzU-OQ_obgofadj_MCxTFCR79fHCUQcAqud0PEDxQGehY8XlGMk51fkRctdOhe7-4Vufx8cnl8uj7_9uXs-Oh83ShRyjWoMrea1bpwNRe8qKRyhSgbYSte1EonVbrc5VJIVRVFA8q2orWlrnjV1rVckffbstdhvJkcRtN7bFzXweDGCQ1nUon0_SJP6Nsn6GacwpCGM0kWecWYYokqt1QTRsTgWnMdfA9hTqXMYoHZmGW7Ztm0WSwwdxaY25T6ZtdgqntnHxLvd56AdzsAsIGuDTA0Hh85LaUuU60V-bjl_vjOzf89gPn09cddKP8BxGShWg</recordid><startdate>201209</startdate><enddate>201209</enddate><creator>Forde, James C.</creator><creator>Marignol, Laure</creator><creator>Blake, Ophelia</creator><creator>McDermott, Ted</creator><creator>Grainger, Ronald</creator><creator>Crowley, Vivien E.</creator><creator>Lynch, Thomas H.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>201209</creationdate><title>Standardization of assay methods reduces variability of total PSA measurements: an Irish study</title><author>Forde, James C. ; Marignol, Laure ; Blake, Ophelia ; McDermott, Ted ; Grainger, Ronald ; Crowley, Vivien E. ; Lynch, Thomas H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4283-a485d60b67eb1217934e728c2d917b4685d3e5e53234977ca4df2fd86919fbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>assay</topic><topic>Biological and medical sciences</topic><topic>Cancer Care Facilities</topic><topic>Cohort Studies</topic><topic>Early Detection of Cancer - methods</topic><topic>Early Detection of Cancer - standards</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunoassay - standards</topic><topic>Ireland</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Reference Standards</topic><topic>Sensitivity and Specificity</topic><topic>total prostate‐specific antigen</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><topic>variability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Forde, James C.</creatorcontrib><creatorcontrib>Marignol, Laure</creatorcontrib><creatorcontrib>Blake, Ophelia</creatorcontrib><creatorcontrib>McDermott, Ted</creatorcontrib><creatorcontrib>Grainger, Ronald</creatorcontrib><creatorcontrib>Crowley, Vivien E.</creatorcontrib><creatorcontrib>Lynch, Thomas H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Forde, James C.</au><au>Marignol, Laure</au><au>Blake, Ophelia</au><au>McDermott, Ted</au><au>Grainger, Ronald</au><au>Crowley, Vivien E.</au><au>Lynch, Thomas H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Standardization of assay methods reduces variability of total PSA measurements: an Irish study</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2012-09</date><risdate>2012</risdate><volume>110</volume><issue>5</issue><spage>644</spage><epage>650</epage><pages>644-650</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><coden>BJINFO</coden><abstract>Study Type – Diagnosis (quality control) Level of Evidence 2b What's known on the subject? and What does the study add? Today, numerous assays for PSA detection are available from various manufacturers. However, these various assays do not detect PSA equally and several studies have demonstrated variability between them. In order to harmonise PSA results and reduce the discrepancies, reference materials are available for assay calibration. We have demonstrated significantly variability between 6 different assay methods currently in use in 9 hospitals despite assay calibration. Variability in PSA values was reduced with the standardisation of the assay method in 4 hospitals. Our results highlight the dilemma of PSA assay variability and stress the need for nationwide standardisation of PSA testing. OBJECTIVE •  To determine whether standardization of total prostate‐specific antigen (tPSA) assay methods reduces variability in tPSA measurements. PATIENTS AND METHODS •  Blood samples from 84 patients attending a single urology department were distributed across nine hospitals selected throughout Ireland for the independent determination of tPSA under the same conditions. •  The selected hospitals collectively used six different assay methods for tPSA detection: Beckman Hybritech WHO Calibrated (used as reference method), Tosoh AIA 1800, Roche E170 (used in three hospitals), Abbott AxSYM, Immulite 2500 2nd Generation (used in two hospitals) and Siemens ADVIA Centaur. •  The method of tPSA detection was next standardized in a subset of four hospitals using the same assay method and the measurements were repeated. •  The difference in mean tPSA in the cohort across the hospitals tested was determined and the Bland–Altman test was used to assess the agreement between each test. Analysis was performed over both the full (0.5–30 µg/L, N= 84) and a narrow (3–7 µg/L, n= 25) tPSA range. RESULTS •  The range and the mean tPSA of the full cohort were inflated across the eight test hospitals, when compared with the reference hospital. •  The poorest agreement between assay methods was associated with a bias of 2.2 ± 2.4 µg/L. The variability in tPSA measurements between assay methods was inconsistent across the range of tPSA values tested and increased with increasing mean tPSA. •  Agreement in reported tPSA was excellent after standardization of tPSA assay methods (bias &lt;0.2 µg/L). •  Over the narrow 3–7 µg/L PSA range, 12/25 (48%) patients had a tPSA range of values across all hospitals in excess of 2 µg/L. Following standardization of the tPSA assay method, patient tPSA ranges were &lt;0.5 µg/L for 13/25 (52%) patients. CONCLUSIONS •  We have shown that the lack of standardization of tPSA assay methods across a panel of Irish hospitals leads to significant variability in the measured tPSA values for the same patient samples. •  Variability in tPSA values was reduced with the standardization of the assay method in four hospitals. •  Standardization of PSA testing on a nationwide scale is warranted.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22897326</pmid><doi>10.1111/j.1464-410X.2011.10923.x</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1464-4096
ispartof BJU international, 2012-09, Vol.110 (5), p.644-650
issn 1464-4096
1464-410X
language eng
recordid cdi_proquest_miscellaneous_1034200175
source MEDLINE; Wiley Online Library All Journals
subjects assay
Biological and medical sciences
Cancer Care Facilities
Cohort Studies
Early Detection of Cancer - methods
Early Detection of Cancer - standards
Gynecology. Andrology. Obstetrics
Humans
Immunoassay - standards
Ireland
Male
Male genital diseases
Medical sciences
Nephrology. Urinary tract diseases
prostate cancer
Prostate-Specific Antigen - blood
Prostatic Neoplasms - diagnosis
Reference Standards
Sensitivity and Specificity
total prostate‐specific antigen
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
variability
title Standardization of assay methods reduces variability of total PSA measurements: an Irish study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A31%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Standardization%20of%20assay%20methods%20reduces%20variability%20of%20total%20PSA%20measurements:%20an%20Irish%20study&rft.jtitle=BJU%20international&rft.au=Forde,%20James%20C.&rft.date=2012-09&rft.volume=110&rft.issue=5&rft.spage=644&rft.epage=650&rft.pages=644-650&rft.issn=1464-4096&rft.eissn=1464-410X&rft.coden=BJINFO&rft_id=info:doi/10.1111/j.1464-410X.2011.10923.x&rft_dat=%3Cproquest_cross%3E1034200175%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1752590040&rft_id=info:pmid/22897326&rfr_iscdi=true